Tuttle Capital Management, a provider of thematic and active ETFs, has forged plans to launch a Short ARKK ETF known as SARK. If approved, it will seek to provide the inverse of ARKK’s performance, betting against all the stocks the ARKK fund buys.
This is big Mark Baum energy “Short everything that [wo]man has touched”
@NeilB It is interesting to go down the time line of this topic. The Fund peaked on 11 Feb. The thread went into radio silence mode after 123 messages on 14 Feb. 7 Aug @Cameron notes the haemorrhage with the funny observation that someone is proposing an inverse fund that bets against everything that ARKK buys.
Of course she personally benefited and has a net worth of c. $250 million. I can only hope that many of the people clamouring on this thread for ARK funds have learnt a thing or two and if they haven’t they should read
You’ve requested an ETF that is currently not available to investors in the UK.
This is because a KIID document is not provided, which means it doesn’t comply with regulations in this country.
A friendly suggestion is to use the search function (at the top of the screen) before requesting a stock in the future, as you can see, what you’re requesting has been covered quite a few times already…
Riiiight. Had not searched as yet, simply just followed prompts from the in-app chat. The UK should rip up that regulation. I’ve been earning great returns from ARK’s funds via an Australian trading account.
The objective of the LS ARKG Genomic Tracker ETP is to track the ARKG Genomic Tracker
Investment Strategy, (the ‘Investment Strategy’) which is designed to provide 1:1 exposure to the
performance of ARK Genomic Revolution ETF (the “Reference Asset”), minus a fee